“Agena proactively sourced and secured materials to provide uninterrupted product availability to our customers. “The unique characteristics of the Agena detection technology provide significant supply chain advantages,” explained Jason Halsey, Senior Vice President of Technology and Operations. With the panel’s release, Agena also aims to alleviate material shortages, enabling laboratories to accelerate testing without concerns about instrument or assay availability. Labs can test large numbers of samples without sacrificing accuracy.” “The iPLEX Pro SARS-CoV-2 Panel exhibits a limit of detection of 0.3 copies per uL. Darryl Irwin, Vice President of Scientific Affairs. “As the number of people being tested increases, panel sensitivity will be critical to ensuring proper patient management,” said Dr. The single-reaction panel targets five regions of the viral genome, providing the accuracy and sensitivity required in the evolving landscape of SARS-CoV-2 testing. The MassARRAY System is the perfect tool for that.” “To address the crisis presented by COVID-19, labs need to cost-effectively process large numbers of samples. “Agena is proud to offer a truly scalable platform to support the increasing demand for high-throughput SARS-CoV-2 testing,” said Peter Dansky, CEO of Agena Bioscience. Priced at under $10 per sample, the panel makes large-scale testing more accessible. FDA’s Emergency Use Authorization program. Clinical laboratories can process more than 6000 samples each day running the assay on a single MassARRAY® instrument, making it one of the highest throughput SARS-CoV-2 tests available under the U.S. Agena Bioscience, a global provider of low cost and high-throughput molecular testing solutions, announced the launch of the iPLEX® Pro SARS-CoV-2 Panel for qualitative detection of the novel coronavirus that causes COVID-19.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |